Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Autores principales: Yap, Timothy A., Walton, Mike I., Hunter, Lisa-Jane K., Valenti, Melanie, de Haven Brandon, Alexis, Eve, Paul D., Ruddle, Ruth, Heaton, Simon P., Henley, Alan, Pickard, Lisa, Vijayaraghavan, Gowri, Caldwell, John J., Thompson, Neil T., Aherne, Wynne, Raynaud, Florence I., Eccles, Suzanne A., Workman, Paul, Collins, Ian, Garrett, Michelle D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944842/
https://ncbi.nlm.nih.gov/pubmed/21191045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0760
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares